Compare

GT Biopharma, Inc. vs Unicycive Therapeutics, Inc. vs Lifevantage Corp vs Scienture Holdings, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearGT Biopharma, Inc.
GTBP
Unicycive Therapeutics, Inc.
UNCY
Lifevantage Corp
LFVN
Scienture Holdings, Inc.
SCNX
Year ended2025-12-312025-12-312026-06-302025-12-31
Revenuen/an/a$182.59M$431.6K
Revenue growth (YoY)n/an/a-20.1%+215.9%
Gross marginn/an/a77.6%76.8%
Operating marginn/an/a3.3%n/m
Net marginn/an/a2.8%n/m
Net income-$28.35M-$26.55M$5.07M-$41.51M
EPS (Diluted)-$6.68-$1.67$0.40-$2.70
Operating cash flow-$12.91M-$31.32M$10.24M-$13.38M
Free cash flown/a-$31.34M$6.67Mn/a
Cash & equivalents$6.81M$29.20Mn/a$6.66M
Total assets$8.11M$49.13M$62.11M$84.18M
Total liabilitiesn/a$18.94M$28.52M$14.06M
Shareholders' equity$5.79M$30.20M$33.59M$70.12M
Return on year-end equity-490.0%-87.9%15.1%-59.2%
Shares outstanding25.53M22.11M12.52M40.63M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearGT Biopharma, Inc.Unicycive Therapeutics, Inc.Lifevantage CorpScienture Holdings, Inc.
Latest$0
Ended 2020-12-31
$675.0K
Ended 2023-12-31
$182.59M
Ended 2026-06-30
$431.6K
Ended 2025-12-31
1 year earlier$0
Ended 2019-12-31
$951.0K
Ended 2022-12-31
$228.53M
Ended 2025-06-30
$136.6K
Ended 2024-12-31
2 years earliern/an/a$200.16M
Ended 2024-06-30
$1.36M
Ended 2023-12-31
3 years earliern/an/a$213.40M
Ended 2023-06-30
$10.25M
Ended 2022-12-31
4 years earliern/an/a$206.36M
Ended 2022-06-30
$9.89M
Ended 2021-12-31